The second clinical scenario considers a 72-year-old patient with multiple myeloma who is triple-class exposed and has experienced disease progression after a BCMA-directed T-cell-engaging therapy.

Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of ...

Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment ...

The FDA cleared the Triton 1 robotic endoscopy system for diagnostic and therapeutic procedures such as colorectal cancer ...

A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility. The European Medicines Agency’s (EMA’s) ...

"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, ...

SOHO 2026 sessions covered chemoimmunotherapy in frontline DLBCL, treatment selection via molecular classifiers, and bispecific antibodies for unfit patients. The 2026 Society of Hematologic Oncology ...

ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases. Published in Practical Radiation ...

Investigators are evaluating cesalatamig among patients with advanced cancer in the international phase 1/2 BiPAVE-001 trial. The FDA has granted fast track designation to cesalatamig (AI-081), an ...

Based on updated data from the TRUST-1 trial, a sNDA for taletrectinib has been approved by the FDA for patients with TKI-naive ROS1+ NSCLC. A supplemental new drug application (sNDA) for ...

Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints. The NCCN has updated its Clinical Practice Guidelines in Oncology ...

Please check back later for more content. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...